Initiated Tecfidera treatment for the first time on or after 27 March 2013 and received at least 6 months of continuous treatment with Tecfidera

Clinical diagnosis of a relapsing form of MS

A baseline measurement for ALC and absolute CD4+ or CD8+ count within 6 months prior to Tecfidera initiation

At least 1 measurement for ALC and absolute CD4+ or CD8+ count while on Tecfidera therapy for at least 6 months

Tecfidera Lymphocyte Chart Review